![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Wielgos Monica Yang Eddy S
Publisher: Future Science
ISSN: 2046-8954
Source: Pharmaceutical Patent Analyst, Vol.2, Iss.6, 2013-11, pp. : 755-766
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry, Vol. 19, Iss. 23, 2012-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Parp Inhibitors for the Treatment of Ovarian Cancer
Current Cancer Drug Targets, Vol. 18, Iss. 9, 2018-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets, Vol. 12, Iss. 3, 2012-03 ,pp. :